Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) rose 5% during trading on Friday. The company traded as high as $17.26 and last traded at $17.6380. 124,335 shares were traded during trading, a decline of 94% from the average daily volume of 2,167,842 shares. The stock had previously closed at $16.80.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, November 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. Canaccord Genuity Group set a $40.00 price target on shares of Tandem Diabetes Care in a research note on Friday, August 7th. William Blair assumed coverage on Tandem Diabetes Care in a report on Friday, August 21st. They set an “outperform” rating for the company. Finally, Truist Financial cut their price objective on shares of Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, September 24th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.39.
Read Our Latest Research Report on Tandem Diabetes Care
Tandem Diabetes Care Stock Up 3.9%
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The business had revenue of $283.69 million for the quarter, compared to analysts’ expectations of $265.85 million. During the same period in the previous year, the firm posted ($0.31) EPS. The business’s revenue was up 13.8% on a year-over-year basis. On average, equities analysts forecast that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current year.
Insider Buying and Selling at Tandem Diabetes Care
In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the business’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the sale, the director owned 24,434 shares of the company’s stock, valued at approximately $467,911.10. The trade was a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Tandem Diabetes Care
Several large investors have recently made changes to their positions in TNDM. State of Tennessee Department of Treasury boosted its holdings in Tandem Diabetes Care by 7.2% during the 3rd quarter. State of Tennessee Department of Treasury now owns 23,652 shares of the medical device company’s stock valued at $386,000 after acquiring an additional 1,582 shares during the period. Public Sector Pension Investment Board lifted its holdings in Tandem Diabetes Care by 0.7% during the third quarter. Public Sector Pension Investment Board now owns 237,049 shares of the medical device company’s stock worth $3,891,000 after buying an additional 1,591 shares during the period. Sterling Capital Management LLC grew its stake in Tandem Diabetes Care by 849.0% in the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 2,080 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Tandem Diabetes Care during the second quarter valued at approximately $33,000. Finally, HighMark Wealth Management LLC grew its stake in Tandem Diabetes Care by 6.4% during the 3rd quarter. HighMark Wealth Management LLC now owns 36,320 shares of the medical device company’s stock worth $592,000 after buying an additional 2,200 shares during the last quarter.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Recommended Stories
- Five stocks we like better than Tandem Diabetes Care
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
